首页> 外文期刊>International Journal of Nanomedicine >A smartphone-assisted pressure-measuring-based diagnosis system for acute myocardial infarction diagnosis
【24h】

A smartphone-assisted pressure-measuring-based diagnosis system for acute myocardial infarction diagnosis

机译:基于智能手机的压力测量诊断系统,用于急性心肌梗死诊断

获取原文
获取外文期刊封面目录资料

摘要

Background: Acute myocardial infarction (AMI), usually caused by atherosclerosis of coronary artery, is the most severe manifestation of coronary artery disease which results in a large amount of death annually. A new diagnosis approach with high accuracy, reliability and low measuring-time-consuming is essential for AMI quick diagnosis. Purpose: The objective of this study was to develop a new point-of-care testing system with high accuracy and reliability for AMI quick diagnosis. Patients and methods: 50 plasma samples of acute myocardial infarction patients were analyzed by developed Smartphone-Assisted Pressure-Measuring-Based Diagnosis System (SPDS). The concentration of substrate was firstly optimized. The effect of antibody labeling and matrix solution on measuring result were then evaluated. And standard curves for cTnI, CK-MB and Myo were built for clinical sample analysis. The measuring results of 50 clinical samples were finally evaluated by comparing with the measuring result obtained by CLIA. Results: The concentration of substrate Hsub2/subOsub2/sub was firstly optimized as 30% to increase measuring signal. A commercial serum matrix was chosen as the matrix solution to dilute biomarkers for standard curve building to minimize matrix effect on the accuracy of clinical plasma sample measuring. The standard curves for cTnI, CK-MB and Myo were built, with measuring dynamic range of 0–25 ng/mL, 0–33 ng/mL and 0–250 ng/mL, and limit of detection of 0.014 ng/mL, 0.16 ng/mL and 0.85 ng/mL respectively. The measuring results obtained by the developed system of 50 clinical plasma samples for three biomarkers matched well with the results obtained by chemiluminescent immunoassay. Conclusion: Due to its small device size, high sensitivity and accuracy, SPDS showed a bright potential for point-of-care testing (POCT) applications.
机译:背景:通常由冠状动脉粥样硬化引起的急性心肌梗塞(AMI)是冠状动脉疾病的最严重表现,每年导致大量死亡。一种具有高精度,可靠性和低耗时性的新诊断方法对于AMI快速诊断至关重要。目的:本研究的目的是开发一种新的即时诊断测试系统,该系统具有较高的准确性和可靠性,可快速诊断AMI。患者和方法:通过开发的基于智能手机的基于压力测量的诊断系统(SPDS)对50例急性心肌梗死患者的血浆样品进行了分析。首先优化底物的浓度。然后评估抗体标记和基质溶液对测量结果的影响。并建立了cTnI,CK-MB和Myo的标准曲线用于临床样品分析。通过与CLIA获得的测量结果进行比较,最终评估了50个临床样品的测量结果。结果:首先优化底物H 2 O 2 的浓度为30%,以增加测量信号。选择商业血清基质作为稀释生物标志物的基质溶液以建立标准曲线,以最大程度地降低基质对临床血浆样品测量准确性的影响。建立了cTnI,CK-MB和Myo的标准曲线,测量动态范围为0–25 ng / mL,0–33 ng / mL和0–250 ng / mL,检测极限为0.014 ng / mL,分别为0.16 ng / mL和0.85 ng / mL。通过开发的系统获得的用于三种生物标志物的50个临床血浆样品的测量结果与化学发光免疫测定获得的结果非常吻合。结论:由于SPDS的体积小,灵敏度高和准确性高,因此在即时检验(POCT)应用中显示出广阔的前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号